FeesSafety
Pluang+

Ether options show 14.1-point implied volatility premium over 30-day realized volatility.

Technical Signals
23 Oct 2026
Tokenpost
View Source
Neutral
Ether options show 14.1-point implied volatility premium over 30-day realized volatility.

Ether (ETH) options displayed a 14.1-point implied volatility premium compared to the asset's 30-day realized volatility as of October 23. The annualized 30-day at-the-money implied volatility was 47.9%, while the realized volatility was 33.8%, indicating that options pricing reflects higher expected future price movement than past price changes. This difference, which varied between 2.7 and 17.5 points from late September to late October, suggests that buyers are paying more for options amid uncertainty, but it does not predict the direction of Ether's price movement. The spread highlights the risk sellers face if realized volatility increases but does not imply mispricing or specific market catalysts.

Ether options volatility premium is the subject, with Pluang market data providing context. For readers following cryptocurrency markets, as of Oct 23, 2026 17:51 WIB, 25 of 50 major cryptocurrencies rose while 23 fell. Notable movers include ONE at Rp26 with a 2.67% gain and 56% sell order activity, CRV at Rp6,582 down 2.46% with 91% sell orders, and KSM at Rp72,936 up 2.42% with 100% buy orders.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
17 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App